# BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

> **NCT00910429** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 237 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Riociguat (Adempas, BAY63-2521)

## Key facts

- **NCT ID:** NCT00910429
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-01
- **Primary completion:** 2019-08-19
- **Final completion:** 2019-08-19
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910429, "BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00910429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*